J Thorac Oncol 2015 Jan;10(1):156-63
*Department of Pneumology, Thoracic Oncology and Respiratory Care Medicine, Mathias Spital Rheine, Rheine, Germany; †Department of Internal Medicine V, Division of Respiratory Medicine and Thoracic Oncology, University of Munich, Thoracic Oncology Centre Munich, Comprehensive Pneumology Center, Member of the German Center for Lung Research, München, Germany; ‡III. Medical Department, University Hospital Mainz, Mainz, Germany; §Department of Medicine 1, University of Wuerzburg, Wuerzburg, Germany; ‖Department of Medicine A, University Hospital, Westfaelische Wilhelms-University, Muenster, Germany; ¶Department of Pneumology and Pulmonary Oncology, Klinikum München, München, Germany; #Department of Pneumologie III, Lungenklinik Hemer, Hemer, Germany; **Privat Clinic, Bonn, Germany; ††Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim am Rhein, Germany; and ‡‡Members of the Afatinib Compassionate Use Consortium (ACUC) are listed in Appendix.